Adolescent and Young Adult Committee

Friday, April 5, 2024 | 9:00 AM – 11:00 AM PT

Room: Chiliwack / 402

Agenda

A. Welcome  Becky Johnson, MD

B. Where are AYAs Treated? Melissa Beauchemin, PhD (virtual)

C. Guest Speaker: Substance Use in AYA Oncology Karen Effinger, MD

D. Guest speaker: What Should the SWOG AYA Committee Prioritize?
   Archie Bleyer, MD

E. Trial Updates:
   • S1823 A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors
     Craig Nichols, MD
   • CTSU/ANHL1931 A Randomized Phase 3 trial of Nivolumab (NSC# 748726
     IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
     Manali Kamdar, MD
   • S1826 A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years)
     with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
     Alex Herrera, MD
   • NCORP Pilot Grant “TALK TO ME: Tailored AYA Trial Messaging”
     Allison Rosen, MS

F. Q&A and discussion Becky Johnson, MD